The aberrant immune response against self-antigens occurring in autoimmune diseases involves dysregulation of members of intracellular signal transduction pathways such as interleukin-2-inducible T cell kinase (ITK) and Janus kinase (JAK). Aclaris Therapeutics Inc. has detailed the characterization of ATI-2138, a dual ITK/JAK3 covalent inhibitor.